Genomic test shows promise as chemotherapy response, survival predictor for women with breast cancer
Tuesday, May 10, 2011 - 15:31
in Health & Medicine
A new genomic test combining multiple signatures a patient's estrogen receptor status, endocrine therapy response, chemotherapy resistance and sensitivity shows promise as a predictor of chemotherapy response and survival benefit in women with invasive breast cancer, according to research led by The University of Texas MD Anderson Cancer Center.